Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 22,448 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pathological Processes Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

TENS Unit for Analgesia During IUD Insertion

NCT06240260
View directory record Official record
Conditions
IUD, Analgesia, Patient Preference, Pain, Acute
Interventions
TENS (transcutaneous electrical nerve stimulation) unit, Standard care
Device · Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
12 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 23, 2026, 6:28 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy

NCT00879060
View directory record Official record
Conditions
Myocardial Fibrosis, Hypertrophic Cardiomyopathy
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 23, 2026, 6:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Understanding Changes in Physical Function Using Principles of Precision Medicine

NCT05581082
View directory record Official record
Conditions
Frailty
Interventions
Pragmatic, exploratory study of Precision Medicine
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
65 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 23, 2026, 6:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Self Selected Population Study of Undiagnosed NAFLD and NASH, Using an Echosens FibroScan, in at Risk Populations

NCT03726827
View directory record Official record
Conditions
NAFLD, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver, Fatty Liver
Interventions
Fibroscan screening
Other
Lead sponsor
Fatty liver Foundation
Other
Eligibility
18 Years and older
Enrollment
1,006 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Texas City, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Oct 23, 2026, 6:28 AM EDT
Enrolling by invitation No phase listed Observational

The Mayo Clinic Rare and Undiagnosed Disease Hackathon

NCT07714161
View directory record Official record
Conditions
Undiagnosed Diseases, Genetic Diseases, Rare Diseases
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 6:28 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

NCT04802161
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia With Multilineage Dysplasia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Interventions
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Liposome-encapsulated Daunorubicin-Cytarabine, Pomalidomide
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
11
States / cities
Atlanta, Georgia • Kansas City, Kansas • Westwood, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 23, 2026, 6:28 AM EDT
Enrolling by invitation Not applicable Interventional

Pivotal Trial of the Boomerang Catheter for pDVA

NCT06311773
View directory record Official record
Conditions
Chronic Limb-Threatening Ischemia
Interventions
Boomerang Catheter
Device
Lead sponsor
Aveera Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
25
States / cities
San Bernardino, California • Sylmar, California • Torrance, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 23, 2026, 6:28 AM EDT
Completed No phase listed Observational

Sexually Transmitted Infections Among African American Women Who Have Sex With Women

NCT01043081
View directory record Official record
Conditions
Sexually Transmitted Infections, HIV Infections
Interventions
Not listed
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Oct 23, 2026, 6:28 AM EDT
Completed Phase 3 Interventional Results available

Management of Skin and Soft Tissue Abscesses in Pediatric Patients After Incision and Drainage

NCT00691600
View directory record Official record
Conditions
Abscess
Interventions
oral trimethoprim/sulfamethoxazole, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
90 Days to 18 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 23, 2026, 6:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

HPV Infections in Older Women

NCT00743392
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
25 Years to 65 Years · Female only
Enrollment
503 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 23, 2026, 6:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Prevention of Postpartum Hemorrhage With Tranexamic Acid

NCT03287336
View directory record Official record
Conditions
Postpartum Hemorrhage
Interventions
Tranexamic Acid
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 23, 2026, 6:28 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Fibrosis Lessens After Metabolic Surgery

NCT06374875
View directory record Official record
Conditions
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity
Interventions
Metabolic surgery, Incretin-Based Therapy
Procedure · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
4
States / cities
Phoenix, Arizona • Indianapolis, Indiana • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 23, 2026, 6:28 AM EDT
Recruiting Not applicable Interventional

Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury

NCT05758077
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Selective Cytopheretic Device, Standard of Care
Device · Other
Lead sponsor
SeaStar Medical
Industry
Eligibility
18 Years and older
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 6:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Performance of Nucleic Acid Amplification Tests for the Detection of NG and CT

NCT02870101
View directory record Official record
Conditions
Neisseria Gonorrhoeae Infection, Chlamydia Trachomatis Infection, Sexually Transmitted Infections
Interventions
Nucleic acid amplification test 1 for NG and CT, Nucleic acid amplification test 2 for NG and CT, Nucleic acid amplification test 3 for NG and CT
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2,767 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
9
States / cities
Hollywood, California • Los Angeles, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 23, 2026, 6:28 AM EDT
Completed Phase 4 Interventional Results available

The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

NCT01842581
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis
Interventions
Rifaximin, Lactulose
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
43
States / cities
Phoenix, Arizona • Coronado, California • Fresno, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 23, 2026, 6:28 AM EDT
Completed Phase 1 Interventional

Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT00735930
View directory record Official record
Conditions
Anemia, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Thrombocytopenia
Interventions
Alvocidib Hydrochloride, Lenalidomide, Pharmacological Study, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Oct 23, 2026, 6:28 AM EDT
Completed Phase 1 Interventional

Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

NCT00962507
View directory record Official record
Conditions
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
everolimus, panobinostat, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 23, 2026, 6:28 AM EDT
Terminated No phase listed Observational

Post-Market Observation Study of Intra-renal Drug Delivery (PROVIDE)

NCT01064895
View directory record Official record
Conditions
Acute Kidney Injury, Acute Renal Failure, Renal Failure Chronic Contrast Induced, Chronic Kidney Disease
Interventions
Benephit catheter for Targeted Renal Therapy
Device
Lead sponsor
Angiodynamics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
15
States / cities
Miami, Florida • Miramar, Florida • Blackfoot, Idaho + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2016 · Synced Oct 23, 2026, 6:28 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Epidemiology and Pathophysiology of Kidney Disease in HFpEF With Obesity

NCT07052539
View directory record Official record
Conditions
Chronic Kidney Disease, Heart Failure With Preserved Ejection Fraction (HFPEF), Obesity (Disorder)
Interventions
High protein and sodium meal
Other
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 23, 2026, 6:28 AM EDT
Terminated Phase 2 Interventional

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

NCT02294357
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Dexamethasone, Prednisone, Methylprednisolone, Lenalidomide, Pomalidomide
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
7
States / cities
Encinitas, California • West Hills, California • West Hollywood, California + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 23, 2026, 6:28 AM EDT
Completed Not applicable Interventional Results available

Epidural Spinal Cord Stimulation for Sensory Restoration and Phantom Limb Pain in Upper-Limb Amputees

NCT02684201
View directory record Official record
Conditions
Phantom Limb
Interventions
Boston Scientific Stimulator Lead
Device
Lead sponsor
Lee Fisher, PhD
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 23, 2026, 6:28 AM EDT
Terminated Phase 2 Interventional

Bortezomib in Treating Patients With Chronic Myelogenous Leukemia

NCT00023881
View directory record Official record
Conditions
Leukemia
Interventions
bortezomib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 23, 2026, 6:28 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

The Bioavailability of a Spray Dried Dispersion Solid Dose Formulation of PF-06260414 Relative to a Suspension Formulation

NCT02393807
View directory record Official record
Conditions
Healthy
Interventions
PF 06260414 solid dose formulation, PF-06260414 nanosuspension
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 23, 2026, 6:28 AM EDT
Withdrawn Phase 2 Interventional

Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML

NCT00003407
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia, Myelodysplastic Syndromes, Neutropenia
Interventions
amifostine trihydrate, cytarabine, mitoxantrone hydrochloride
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
4
States / cities
Chicago, Illinois • Kankakee, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 23, 2026, 6:28 AM EDT